Dextran-coated iron oxide nanoparticle for delivery of miR-29a to breast cancer cell line

References

• Aigner A. 2007. Nonviral in vivo delivery of therapeutic small interfering RNAs. Curr Opin Mol Ther. 9:345–352.
   PubMed Web of Science ®Google Scholar
• Akinc A, Thomas M, Klibanov AM, Langer R. 2005. Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med. 7:657–663.
   PubMed Web of Science ®Google Scholar
• Baker JR. Jr 2009. Dendrimer-based nanoparticles for cancer therapy. Hematol Am SocHematol Educ Program. 2009:708–719.
   Google Scholar
• Cai K, Shen F, Cui JH, Yu Y, Pan HQ. 2015. Expression of miR-221 in colon cancer correlates with prognosis. Int J Clin Exp Med. 8:2794–2798.
   PubMed Web of Science ®Google Scholar
• Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, Soltoff S. 1991. Oncogenes and signal transduction. Cell. 64:281–302.
   PubMed Web of Science ®Google Scholar
• Chen Y, Gao D-Y, Huang L. 2015. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev. 81:128–141.
   PubMed Web of Science ®Google Scholar
• Di Leva G, Garofalo M, Croce CM. 2014. MicroRNAs in cancer. Annu Rev Pathol. 9:287–314.
   PubMed Web of Science ®Google Scholar
• Farazi TA, Spitzer JI, Morozov P, Tuschl T. 2011. MiRNAs in human cancer. J Pathol. 223:102–115.
   PubMed Web of Science ®Google Scholar
• Feng SS. 2004. Nanoparticles of biodegradable polymers for new-concept chemotherapy. Expert Rev Med Devices. 1:115–125.
   PubMed Web of Science ®Google Scholar
• Gaitanis A, Staal S. 2010. Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use. Methods Mol Biol. 624:385–392.
   PubMedGoogle Scholar
• Giordano S, Columbano A. 2013. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology. 57:840–847.
   PubMed Web of Science ®Google Scholar
• Hawkins MJ, Soon-Shiong P, Desai N. 2008. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev. 60:876–885.
   PubMed Web of Science ®Google Scholar
• Hayes J, Peruzzi PP, Lawler S. 2014. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 20:460–469.
   PubMed Web of Science ®Google Scholar
• Hesong J, Guang Z, Jun-Hua W, Chun-Pıng J. 2014. Diverse roles of miR-29a in cancer. Oncol Rep. 31:1509–1516.
   PubMed Web of Science ®Google Scholar
• Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR, Chan KK, et al. 2013. Targeted delivery of microRNA-29b by transferrin conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res. 19:2355–2367.
   PubMed Web of Science ®Google Scholar
• Jain RK, Stylianopoulos T. 2010. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 7:653–664.
   PubMed Web of Science ®Google Scholar
• Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D. 2013. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog. 52:297–303.
   PubMed Web of Science ®Google Scholar
• Kasinski AL, Slack FJ. 2011. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 11:849–864.
   PubMed Web of Science ®Google Scholar
• Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. 2012. microRNAs in cancer management. Lancet Oncol. 13:e249–e258.
   PubMed Web of Science ®Google Scholar
• Kurtanich T, Roos N, Wang G, Yang J, Wang A, Chung EJ. 2018. Pancreatic cancer gene therapy delivered by nanoparticles. SLAS Technol. 24:151–160.
   PubMed Web of Science ®Google Scholar
• Lasic DD. 1996. Doxorubicin in sterically stabilized liposomes. Nature. 380:561–562.
   PubMed Web of Science ®Google Scholar
• Levine AJ, Momand J, Finlay CA. 1991. The p53 tumour suppressor gene. Nature. 351:453–456.
   PubMed Web of Science ®Google Scholar
• Li F, Wang F, Zhu C, Wei Q, Zhang T, Zhou YL. 2018. miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker. Int J Nanomedicine. 13:2295–2307.
   PubMed Web of Science ®Google Scholar
• Li Z, Rana TM. 2014. Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov. 13:622–638.
   PubMed Web of Science ®Google Scholar
• Li ZH, Xiong QY, Xu L, Duan P, Yang QO, Zhou P, Tu JH. 2017. miR-29a regulated ER-positive breast cancer cell growth and invasion and is involved in the insulin signaling pathway. Oncotarget. 8:32566–32575.
   PubMedGoogle Scholar
• Minelli C, Lowe SB, Stevens MM. 2010. Engineering nanocomposite materials for cancer therapy. Small. 6:2336–2357.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. 2005. Nanomedicine: current status and future prospects. Faseb J. 19:311–330.
   PubMed Web of Science ®Google Scholar
• Muniyappa MK, Dowling P, Henry M, Meleady P, Doolan P, Gammell P, Clynes M, Barron N. 2009. MiR-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell lines. Eur J Cancer. 45:3104–3118.
   PubMed Web of Science ®Google Scholar
• Perepelyuk M, Sacko K, Thangavel K, Shoyele SA. 2018. Evaluation of MUC1-aptamer functionalized hybrid nanoparticles for targeted delivery of miRNA-29b to nonsmall cell lung cancer. Mol Pharmaceutics. 15:985–993.
   PubMed Web of Science ®Google Scholar
• Reid G, Kirschner MB, Van ZN. 2011. Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol. 80:193–208.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. 2012. Cancer statistics. CA Cancer J Clin. 62:10–29.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. 2017. Colorectal cancer statistics, 2017. CA Cancer J Clin. 67:177–193.
   PubMed Web of Science ®Google Scholar
• Srivastava SK, Bhardwaj A, Singh S, Arora S, Wang B, Grizzle WE, Singh AP. 2011. MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. Carcinogenesis. 32:1832–1839.
   PubMed Web of Science ®Google Scholar
• Steichen SD, Caldorera-Moore M, Peppas NA. 2013. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci. 48:416–427.
   PubMed Web of Science ®Google Scholar
• Sun L, Hu J, Xiong W, Chen X, Li H, Jie S. 2013. MicroRNA expression profiles of circulating microvesicles in hepatocellular carcinoma. Acta Gastroenterol Belg. 76:386–392.
   PubMed Web of Science ®Google Scholar
• Van Rooij E, Kauppinen S. 2014. Development of microRNA therapeutics is coming of age. EMBO Mol Med. 6:851–864.
   PubMed Web of Science ®Google Scholar
• Van Rooij E, Olson EN. 2012. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov. 11:860–872.
   PubMed Web of Science ®Google Scholar
• Wang AZ, Langer R, Farokhzad OC. 2012. Nanoparticle delivery of cancer drugs. Annu Rev Med. 63:185–198.
   PubMed Web of Science ®Google Scholar
• Wang M, Thanou M. 2010. Targeting nanoparticles to cancer. Pharmacol Res. 62:90–99.
   PubMed Web of Science ®Google Scholar
• Wu Z, Huang X, Huang X, Zou Q, Guo Y. 2013. The inhibitory role of Mir-29 in growth of breast cancer cells. J Exp Clin Cancer Res. 32:98.
   PubMed Web of Science ®Google Scholar
• Xu Y, Pang L, Wang H, Xu C, Shah H, Guo P, Shu D, Qian SY. 2019. Specific delivery of delta-5 desaturase siRNA via RNA nanoparticles supplemented with dihomo-γ-linolenic acid for colon cancer suppression. Redox Biol. 21:101085.
   PubMed Web of Science ®Google Scholar
• Yang J, Liu Y, Wang H, Liu L, Wang W, Wang C, Wang Q, Liu W. 2012. The biocompatibility of fatty acid modified dextran-agmatine bioconjugate gene delivery vector. Biomaterials. 33:604–613.
   PubMed Web of Science ®Google Scholar
• Zheng B, Chen L, Pan CC, Wang JZ, Lu GR, Yang SX, Xue ZX, Wang FY, Xu CL. 2018. Targeted delivery of miRNA-204-5p by PEGylated polymer nanoparticles for colon cancer therapy. Nanomedicine (Lond). 13:769–785.
   PubMed Web of Science ®Google Scholar